Optimizing empiric antibiotic therapy in patients with severe β-lactam allergy

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5918-5923

  Koliscak, Lindsey P ^a,b   Johnson, James W ^a,c   Beardsley, James R ^a   Miller, David P ^c   Williamson, John C ^a,c   Luther, Vera P ^c   Ohl, Christopher A ^c  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WINGATE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIUM CULTURE; BLOOD CULTURE; BLOODSTREAM INFECTION; BROTH DILUTION; CATHETER INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS; RETROSPECTIVE STUDY; RISK FACTOR; URINARY TRACT INFECTION; URINE CULTURE; DRUG COMBINATION; DRUG EFFECTS; EMPIRICAL RESEARCH; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA, BACTERIAL; RISK; URINARY TRACT INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EMPIRICAL RESEARCH; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK; TETRACYCLINE; URINARY TRACT INFECTIONS;

EID: 84887431243     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01202-13     Document Type: Article

References (21)

1. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micke ST, Kollef MH. 2008. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibioticresistant gram-negative bacteria. Chest 134:281-287.
2. American Thoracic Society and the Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
3. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. 2006. Using local microbiologic data to develop institutionspecific guidelines for the treatment of hospital-acquired pneumonia. Chest 130:787-793.
4. Burgess DS, Abate BJ. 2005. Antimicrobial regimen selection, p 1909-1919. In DiPiro JT, Talbert RT, Yee GC, Matzke GR, Wells BG, Posey LM (ed), Pharmacotherapy: a pathophysiologic approach, 6th ed. The McGraw-Hill Companies, Inc., New York, NY.
5. Prabaker P, Weinstein RA. 2011. Trends in antimicrobial resistance in intensive care units in the United States. Curr. Opin. Crit. Care 17:472-479.
6. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ, EMERGEncy Study ID NET Group. 2008. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin. Infect. Dis. 47:1150-1158.
7. CLSI. 2009. Analysis and presentation of cumulative antimicrobial susceptibility test data: approved guideline-3rd ed. CLSI document M39-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Christoff J, Tolentino J, Mawdsley E, Matushek S, Weber SG. 2010. Optimizing empirical antimicrobial therapy for infection due to Gramnegative pathogens in the intensive care unit: utility of a combination antibiogram. Infect. Control Hosp. Epidemiol. 31:256-261.
9. Gruchalla RS, Pirmohamed M. 2006. Antibiotic allergy. N. Engl. J. Med. 354:601-609.
10. Saxon A, Beall GN, Rohr AS, Adelman DC. 1987. Immediate hypersensitivity reactions to β-lactam antibiotics. Ann. Intern. Med. 107:204-215.
11. Frumin J, Gallagher JC. 2009. Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances? Ann. Pharmacother. 43:304-315.
12. Gasink LB, Fishman NO, Nachamkin I, Bilker WB. 2007. Risk factors for impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 28:1175-1180.
13. Pop-Vicas A, Tacconelli E, Gravenstein S, Lu B, D'Agata EM. 2009. Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infect. Control Hosp. Epidemiol. 30:325-331.
14. Pena C, Suarex C, Tubau F, Dominguez A, Sora M, Pujol M, Gudiol F, Ariza J. 2009. Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 28:519-522.
15. Seguin P, Redun Y, Laviolle B, Nesseler N, Donnio PY, Malledant Y. 2010. Risk factors for multidrug-resistant bacteria in patients with postoperative peritonitis requiring intensive care. J. Antimicrob. Chemother. 65:342-346.
16. Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micke S, Kollef M. 2011. Impact of previous antibiotic therapy on outcome of Gramnegative sepsis. Crit. Care Med. 39:1859-1865.
17. Solensky R, Khan DA. 2010. Drug allergy: an updated practice parameter. Ann. Allergy Asthma Immunol. 105:259-273.
18. Koliscak LP, Johnson JW, Beardsley JR, Williamson JC, Luther VP, Ohl CA. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, abstr K-325.
19. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement, CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Luna CM, Vujacich P, Neiderman MS, Vay C, Gherardi C, Matera J, Jolly EC. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685.
21. Kollef MH, Sherman G, Ward S, Fraser VJ. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.